Journal
JOURNAL OF CELLULAR BIOCHEMISTRY
Volume 118, Issue 12, Pages 4575-4586Publisher
WILEY
DOI: 10.1002/jcb.26122
Keywords
ANDROGRAPHOLIDE; CELL CYCLE ARREST; APOPTOSIS; TCF-1; SOX9; CHONDROSARCOMA
Categories
Funding
- Medical Scientific Research Foundation of Guangdong Province [34216014]
- China Postdoctoral Science Foundation [2016M602606]
- Macau Foundation for Development of Science and Technology [111/2015/A]
- Natural Science Foundation of Guangdong Province [2014A030310242]
- National Natural Science Foundation of China [81602360, 81672224]
Ask authors/readers for more resources
Chondrosarcoma is the second most malignant bone tumor with poor prognosis and limited treatment options. Thus, development of more effective treatments has become urgent. Recently, natural compounds derived from medicinal plants have emerged as promising therapeutic options via targeting multiple key cellular molecules. Andrographolide (Andro) is such a compound, which has previously been shown to induce cell cycle arrest and apoptosis in several human cancers. However, the molecular mechanism through which Andro exerts its anti-cancer effect on chondrosarcoma remains to be elucidated. In the present study, we showed that Andro-induced G2/M cell cycle arrest of chondrosarcoma by fine-tuning the expressions of several cell cycle regulators such as p21, p27, and Cyclins, and that prolonged treatment of cells with Andro caused pronounced cell apoptosis. Remarkably, we found that SOX9 was highly expressed in poor-differentiated chondrosarcoma, and that knockdown of SOX9 suppressed chondrosarcoma cell growth. Further, our results showed that Andro dose-dependently down-regulated SOX9 expression in chondrosarcoma cells. Concomitantly, an inhibition of T cell factor 1 (TCF-1) mRNA expression and an enhancement of TCF-1 protein degradation by Andro were observed. In contrast, the expression and subcellular localization of -catenin were not altered upon the treatment of Andro, suggesting that -catenin might not function as the primary target of Andro. Additionally, we provided evidence that there was a mutual regulation between TCF-1 and SOX9 in chondrosarcoma cells. In conclusion, these results highlight the potential therapeutic effects of Andro in treatment of chondrosarcoma via targeting the TCF-1/SOX9 axis. J. Cell. Biochem. 118: 4575-4586, 2017. (c) 2017 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available